Glasgow Prognostic Score for Prediction of Chemotherapy-triggered Acute Exacerbation Interstitial Lung Disease in Patients with Small Cell Lung Cancer

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2021 May 3

PMID 33939332

Citations 6

Authors

Ryota Kikuchi

Hiroyuki Takoi

Takao Tsuji

Yoko Nagatomo

Akane Tanaka

Hayato Kinoshita

Mariko Ono

Mayuko Ishiwari

Kazutoshi Toriyama

Yuta Kono

Yuki Togashi

Kazuhiro Yamaguchi

Akinobu Yoshimura

Shinji Abe

Affiliations

Soon will be listed here.

Abstract

Background: Predicting the incidence of chemotherapy-triggered acute exacerbation of interstitial lung disease (AE-ILD) in patients with lung cancer is important because AE-ILD confers a poor prognosis. The Glasgow prognostic score (GPS), which is an inflammation-based index composed of serum levels of C-reactive protein and albumin, predicts prognosis in patients with small cell lung cancer (SCLC) without ILD. In this study, we investigated AE-ILD and survival outcome based on the GPS in patients with ILD associated with SCLC who were receiving chemotherapy.

Methods: Medical records of patients who received platinum-based first-line chemotherapy between June 2010 and May 2019 were retrospectively reviewed to compare the incidence of AE-ILD and overall survival (OS) between GPS 0, 1, and 2.

Results: Among our cohort of 31 patients, six (19.3%) experienced chemotherapy-triggered AE-ILD. The AE-ILD incidence increased from 9.5% to 25.0% and 50.0% with increase in GPS of 0, 1, and 2, respectively. Univariate and multivariate analyses revealed remarkable associations between GPS 2 and both AE-ILD (odds ratio for GPS 2, 18.69; p = 0.046) and prognosis (hazard ratio of GPS 2, 13.52; p = 0.002). Furthermore, median OS in the GPS 0, 1, and 2 groups was 16.2, 9.8, and 7.1 months, respectively (p < 0.001).

Conclusions: Our results suggest that GPS 2 is both a predictor of risk of chemotherapy-triggered AE-ILD and a prognostic indicator in patients with ILD associated with SCLC. We propose that GPS may be used as a guide to distinguish chemotherapy-tolerant patients from those at high risk of AE-ILD.

Citing Articles

Impact of interstitial lung disease gender-age-physiology index in surgically treated lung cancer.

Sakamoto S, Kawakita N, Takeuchi T, Sumitomo H, Miyamoto N, Toba H Int J Clin Oncol. 2024; 29(10):1475-1482.

PMID: 39180709 DOI: 10.1007/s10147-024-02600-5.

Prognostic significance of antifibrotic agents in idiopathic pulmonary fibrosis after initiation of long-term oxygen therapy.

Ishiwari M, Kono Y, Togashi Y, Kobayashi K, Kikuchi R, Kogami M Sarcoidosis Vasc Diffuse Lung Dis. 2024; 41(1):e2024002.

PMID: 38567555 PMC: 11008323. DOI: 10.36141/svdld.v41i1.15264.

Risk factors for acute exacerbation of interstitial lung disease during chemotherapy for lung cancer: a systematic review and meta-analysis.

Wang Z, Bai J, Liu Y, Li P, Jiao G Front Oncol. 2023; 13:1250688.

PMID: 37886172 PMC: 10598856. DOI: 10.3389/fonc.2023.1250688.

The role of miR1 and miR133a in new-onset atrial fibrillation after acute myocardial infarction.

Zeng Q, Li W, Luo Z, Zhou H, Duan Z, Xiong X BMC Cardiovasc Disord. 2023; 23(1):448.

PMID: 37697243 PMC: 10496401. DOI: 10.1186/s12872-023-03462-x.

Impact of sarcopenia on chemotherapy-triggered exacerbation of interstitial lung disease in patients with non-small cell lung cancer.

Kikuchi R, Takoi H, Ishiwari M, Toriyama K, Kono Y, Togashi Y Thorac Cancer. 2021; 13(4):549-556.

PMID: 34964266 PMC: 8841712. DOI: 10.1111/1759-7714.14294.

References

Li B, Zhang X, Xu G, Zhang S, Song H, Yang K . Serum prealbumin is a prognostic indicator in idiopathic pulmonary fibrosis. Clin Respir J. 2019; 13(8):493-498. DOI: 10.1111/crj.13050. View

Togashi Y, Masago K, Handa T, Tanizawa K, Okuda C, Sakamori Y . Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer. Clin Lung Cancer. 2011; 13(4):304-11. DOI: 10.1016/j.cllc.2011.11.001. View

Song M, Lim S, Park J, Yoon H, Lee J, Kim S . Prognosis of Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis: Assessment according to GAP Stage. J Oncol. 2019; 2019:5437390. PMC: 6521435. DOI: 10.1155/2019/5437390. View

Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y . Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med. 2008; 177(12):1348-57. DOI: 10.1164/rccm.200710-1501OC. View

Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T . Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 2007; 97(2):162-9. PMC: 2360311. DOI: 10.1038/sj.bjc.6603810. View

Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt W . The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016; 11(1):39-51. DOI: 10.1016/j.jtho.2015.09.009. View

Travis W, Costabel U, Hansell D, King Jr T, Lynch D, Nicholson A . An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013; 188(6):733-48. PMC: 5803655. DOI: 10.1164/rccm.201308-1483ST. View

Park J, Kim D, Shim T, Lim C, Koh Y, Lee S . Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2001; 17(6):1216-9. DOI: 10.1183/09031936.01.99055301. View

Ozawa Y, Suda T, Naito T, Enomoto N, Hashimoto D, Fujisawa T . Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 2009; 14(5):723-8. DOI: 10.1111/j.1440-1843.2009.01547.x. View

10.

Sato T, Teramukai S, Kondo H, Watanabe A, Ebina M, Kishi K . Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2013; 147(5):1604-1611.e3. DOI: 10.1016/j.jtcvs.2013.09.050. View

11.

Lee T, Park J, Lee H, Cho Y, Yoon H, Lee J . Lung cancer in patients with idiopathic pulmonary fibrosis: clinical characteristics and impact on survival. Respir Med. 2014; 108(10):1549-55. DOI: 10.1016/j.rmed.2014.07.020. View

12.

Kenmotsu H, Naito T, Mori K, Ko R, Ono A, Wakuda K . Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. Cancer Chemother Pharmacol. 2015; 75(3):521-6. DOI: 10.1007/s00280-014-2670-y. View

13.

Camus P . Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management. Br J Cancer. 2004; 91 Suppl 2:S1-2. PMC: 2750812. DOI: 10.1038/sj.bjc.6602060. View

14.

Barczi E, Nagy T, Starobinski L, Kolonics-Farkas A, Eszes N, Bohacs A . Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival. Thorac Cancer. 2020; 11(7):1911-1917. PMC: 7327688. DOI: 10.1111/1759-7714.13481. View

15.

Aubry M, Myers J, Douglas W, Tazelaar H, Washington Stephens T, Hartman T . Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin Proc. 2002; 77(8):763-70. DOI: 10.4065/77.8.763. View

16.

Kurishima K, Watanabe H, Ishikawa H, Satoh H, Hizawa N . Modified glasgow prognostic score in patients with small-cell lung cancer. Mol Clin Oncol. 2017; 7(1):121-124. PMC: 5492645. DOI: 10.3892/mco.2017.1261. View

17.

Forrest L, McMillan D, McArdle C, Angerson W, Dunlop D . Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003; 89(6):1028-30. PMC: 2376960. DOI: 10.1038/sj.bjc.6601242. View

18.

Kreuter M, Ehlers-Tenenbaum S, Schaaf M, Oltmanns U, Palmowski K, Hoffmann H . Treatment and outcome of lung cancer in idiopathic interstitial pneumonias. Sarcoidosis Vasc Diffuse Lung Dis. 2015; 31(4):266-74. View

19.

Song J, Hong S, Lim C, Koh Y, Kim D . Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2010; 37(2):356-63. DOI: 10.1183/09031936.00159709. View

20.

Forrest L, McMillan D, McArdle C, Angerson W, Dunlop D . Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer. 2004; 90(9):1704-6. PMC: 2409737. DOI: 10.1038/sj.bjc.6601789. View